15 research outputs found
Attività intramacrofagica di nuovi agenti antitubercolari per il trattamento delle infezioni sostenute da ceppi MDR mediante inibizione selettiva della RNA polimerasi.
Inibizione selettiva della RNA polimerasi in isolati clinici di M. tuberculosis RMP-resistenti e MDR mediante derivati dell’acido fenazin-1-carbossilico
Phenazine-1-carboxilyc acid derivatives suppressing the RNA polymerase as potential agents for the treatment of infections sustained by drug-resistant and MDR Mycobacterium tuberculosis
Derivati fenazinici come potenziali agenti per il trattamento delle infezioni sostenute da M. tuberculosis resistenti e multiresistenti
7-Alkylamino-6-nitrotetrazolo[1,5-a]pyrimidines as precursors of anomalous nucleosides and heterocycles with potential antiseptic activity
l-Proline catalyzed condensation of salicylaldehydes with ethyl nitroacetate: an efficient access to 3-nitrocoumarins
The plasma metabolome of Atlantic salmon as studied by 1H NMR spectroscopy using standard operating procedures: effect of aquaculture location and growth stage
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 198
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2
Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8 666 000 cases) and Russia (4 162 000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become availabl